Jochen Wilke

Furth, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Functional differences between CLL- and ALL-derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL-10 as potential modulatory targets.

Functional differences between CLL- and ALL-derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL-10 as potential modulatory targets.

Journal: HemaSphere

Published: July 04, 2025

3D Tumor microenvironment interaction reveals AP-1 complex regulation and contact-mediated reprogramming of bone marrow stromal cells in chronic lymphocytic leukemia.

3D Tumor microenvironment interaction reveals AP-1 complex regulation and contact-mediated reprogramming of bone marrow stromal cells in chronic lymphocytic leukemia.

Journal: HemaSphere

Published: March 26, 2025

Correction: Prognostic and predictive impact of NOTCH1 in early breast cancer.

Correction: Prognostic and predictive impact of NOTCH1 in early breast cancer.

Journal: Breast cancer research and treatment

Published: November 20, 2024

Prognostic and predictive impact of NOTCH1 in early breast cancer.

Prognostic and predictive impact of NOTCH1 in early breast cancer.

Journal: Breast cancer research and treatment

Published: February 26, 2024

The moderating role of moral disengagement on the relation between bullying and school well-being in adolescents.

The moderating role of moral disengagement on the relation between bullying and school well-being in adolescents.

Journal: BMC psychology

Published: October 13, 2023

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315).

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315).

Journal: JTO clinical and research reports

Published: September 21, 2023

Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma.

Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma.

Journal: Cells

Published: November 07, 2021

Immune modulatory effects of Idelalisib in stromal cells of chronic lymphocytic leukemia.

Immune modulatory effects of Idelalisib in stromal cells of chronic lymphocytic leukemia.

Journal: Leukemia & lymphoma

Published: May 17, 2021

The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer Agents.

The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer Agents.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 06, 2021

Protein kinase C-β-dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia.

Protein kinase C-β-dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia.

Journal: Stem cells (Dayton, Ohio)

Published: October 09, 2020

A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung).

A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung).

Journal: Frontiers in pharmacology

Published: September 24, 2020

A brief instrument to measure health-related quality-of-life in patients with bone metastasis: validation of the German version of Bone Metastases Quality-of-Life-10 (BOMET-QoL-10).

A brief instrument to measure health-related quality-of-life in patients with bone metastasis: validation of the German version of Bone Metastases Quality-of-Life-10 (BOMET-QoL-10).

Journal: Journal of medical economics

Published: June 07, 2018

Showing 1-12 of 13

Last Updated: 09/26/2026